Peer Review History: Efficacy and Safety of Adalimumab 40 mg Weekly Dosingin Patients with Resistant Psoriasis

Open Peer Review Policy: Click Here

Specific Comment:

Average Peer review marks at initial stage: 7.75/10

Average Peer review marks at publication stage: 9/10

Peer Review History:


Stage 1 | Original Manuscript | File 1 | NA 


Stage 1 | Peer review report_1 (Dnyaneshwar Jadhav, India) | File 1 | NA 


Stage 1 | Peer review report_2 (Arfan Ul Bari, Pakistan) | File 1 | File 2 


Stage 1 | Revised_MS_v1_and_Feedback_v1 | File 1 | File 2 


Stage 1 | Comment_Editor_1_v1 | File 1 | NA